Search

This article, published in Aging Cell, explores the topic of healthy aging and the various factors that influence it. The authors emphasize the need for a holistic approach to understanding and promoting healthy aging, considering biological pathways, holistic approaches, and interventions targeting multiple organ systems and mechanistic pathways. The article discusses specific topics such as senescent cells, NAD metabolism, genetic variants in centenarians, the African killifish as a model organism, organ crosstalk, cardiorespiratory fitness, and behavioral interventions. The authors also highlight the challenges and future directions in the field of healthy aging research. [Extracted from the article]

Sustainable exercise strategies are needed for older adults to maintain aerobic capacity and strength. The objective of this pilot in 6 adults ≥ 65 years of age was to determine the feasibility and preliminary efficacy of high-intensity functional circuit training which does not require stationary equipment. Instructor-led small group exercise classes were held 3x/week for 12 weeks using weight-bearing exercises performed in a circuit format at ratings of perceived exertion (RPE) of 6–8/10. All 6 participants completed the pilot and showed significant improvements by the Wilcoxon signed-rank test. The six-minute walk distance increased 10.5%. Timed arm curl and chair stands increased 26.8% and 30.3% (all p ≤ 0.03). These preliminary findings suggest that high-intensity functional circuit exercise is feasible in older adults and increases functional measures of aerobic capacity and strength. Further research is warranted to develop this strategy which has the potential for broad dissemination without the need for a traditional exercise facility. [ABSTRACT FROM AUTHOR]

Background Biomarkers that provide insight into drivers of aging are needed for people with human immunodeficiency virus (PWH). The study objective was to determine if epigenetic age acceleration (EAA) markers are associated with physiologic frailty measured by the Veterans Aging Cohort Study (VACS) Index and predict all-cause mortality for PWH. Methods Epigenome-wide DNA methylation was profiled in VACS total white blood cell samples collected during 2005–2007 from 531 PWH to generate 6 established markers of EAA. The association of each EAA marker was tested with VACS Index 2.0. All-cause mortality was assessed over 10 years. For each EAA marker, the hazard ratio per increased year was determined using Cox regression. To evaluate mortality discrimination, C-statistics were derived. Results Participants were mostly men (98.5%) and non-Hispanic Black (84.4%), with a mean age of 52.4 years (standard deviation [SD], 7.8 years). Mean VACS Index score was 59.3 (SD, 16.4) and 136 deaths occurred over a median follow-up of 8.7 years. Grim age acceleration (AA), PhenoAA, HannumAA, and extrinsic epigenetic AA were associated with the VACS Index and mortality. HorvathAA and intrinsic epigenetic AA were not associated with either outcome. GrimAA had the greatest mortality discrimination among EAA markers and predicted mortality independently of the VACS Index. One-year increase in GrimAA was associated with a 1-point increase in VACS Index and a 10% increased hazard for mortality. Conclusions The observed associations between EAA markers with physiologic frailty and mortality support future research to provide mechanistic insight into the accelerated aging process and inform interventions tailored to PWH for promoting increased healthspan. [ABSTRACT FROM AUTHOR]

Polypharmacy is associated with frailty in the general population, but little is known about polypharmacy among persons living with HIV (PLWH) on antiretroviral (ARV) therapy. We determined the association between polypharmacy and an adapted frailty-related phenotype (aFRP) via a cross-sectional study in FY 2009 of 1762 PLWH on ARV with suppressed viral load and 2679 uninfected participants in the Veterans Aging Cohort Study. The primary predictor was number of chronic outpatient non-ARV medications using pharmacy fill/refill data. The outcome was self-report of four aFRP domains: shrinking, exhaustion, slowness, low physical activity. Frailty was defined as reporting 3–4 domains while pre-frailty was 1–2. Frailty was uncommon (2% PLWH, 3% uninfected); a larger proportion demonstrated any aFRP domain (31% PLWH, 41% uninfected). Among PLWH and uninfected, median chronic non-ARV medications was 6 and 16 respectively if having any aFRP domain, and 4 and 10 when without aFRP domains. In adjusted analyses, each additional chronic non-ARV medication conferred an 11% increased odds of having any aFRP domain in PLWH (OR [95% CI] = 1.11 [1.08, 1.14]), and a 4% increase in those uninfected (OR [95% CI] = 1.04 [1.03, 1.04]). The stronger association between polypharmacy and frailty in PLWH warrants further study and potential deprescribing of medications. [ABSTRACT FROM AUTHOR]